| Group | Total | Number and percentage positive (with 95% exact confidence interval) | ||||||||
| CAGE | GBU 4–5 | HER2 | p53 | c-myc | NY-ES0-1 | MUC1 | Panel 1/4 | Panel 1/7 | ||
| All LC | ||||||||||
| n | 104 | 29*** | 21*** | 13** | 12* | 12*** | 19*** | 36*** | 71*** | 79*** |
| % +ve (95% CI) | 28 (20 to 38) | 20 (13 to 29) | 13 (7 to 20) | 12 (6 to 19) | 12 (6 to 19) | 18 (11 to 27) | 35 (26 to 45) | 68 (58 to 77) | 76 (67 to 84) | |
| SCLC | ||||||||||
| n | 22 | 5* | 4** | 4* | 4* | 2* | 1 NS | 8*** | 12*** | 15*** |
| % +ve (95% CI) | 23 (8 to 45) | 18 (5 to 40) | 18 (5 to 40) | 18 (5 to 40) | 9 (1 to 29) | 5 (0 to 23) | 36 (17 to 59) | 55 (32 to 76) | 68 (45 to 86) | |
| NSCLC | ||||||||||
| n | 82 | 24*** | 17*** | 9* | 8 NS | 10*** | 18*** | 28*** | 59*** | 64*** |
| % +ve (95% CI) | 29 (20 to 40) | 21 (13 to 31) | 11 (5 to 20) | 10 (4 to 18) | 12 (6 to 21) | 22 (14 to 32) | 34 (24 to 45) | 72 (61 to 81) | 78 (68 to 86) | |
| Normal | ||||||||||
| n | 50 | 2 | 0 | 1 | 1 | 0 | 1 | 0 | 3 | 4 |
| % +ve (95% CI) | 4 (0 to 14) | 0 (0 to 7) | 2 (0 to 11) | 2 (0 to 11) | 0 (0 to 7) | 2 (0 to 11) | 0 (0 to 7) | 6 (1 to 17) | 8 (2 to 19) | |
| Specificity (%) | 50 | 96 | 100 | 98 | 98 | 100 | 98 | 100 | 94 | 92 |
Number (n) and percentage positivity (% +ve) with 95% confidence interval (95% CI) in each patient group. Positivity was defined as a value greater than the mean of the normal population plus 2SD for GBU4–5 and CAGE, or mean plus 3SD for the other assays.
*Denotes p value relative to normal control plasma. *p<0.05; **p<0.01; ***p<0.001; NS, not significant p>0.05 (χ2 analysis).
All LC, all lung cancer samples tested; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; Normal, normal blood donor plasma; Panel 1/4 or 1/7 denotes raised levels of at least one autoantibody of the panel; panel of 4: CAGE, GBU4-5; NY-ESO-1, MUC1 antigens only.